Major Program
Cancer Prevention Clinical Trials Network
Research Group
Gastrointestinal and Other Cancers
Sponsor
National Cancer Institute (NCI)
Status
Recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT05107219
This early phase I trial studies the guanylyl cyclase C (GCC) agonist effect on cGMP signal
in duodenal tissue. Plecanatide and linaclotide are drugs approved by the Food and Drug
Administration for the treatment of conditions related to constipation. This trial aims to
see the effects of taking either one of two drugs, plecanatide or linaclotide, or no drug, on
a certain chemical found in the tissue collected from small intestine and how they compare.
in duodenal tissue. Plecanatide and linaclotide are drugs approved by the Food and Drug
Administration for the treatment of conditions related to constipation. This trial aims to
see the effects of taking either one of two drugs, plecanatide or linaclotide, or no drug, on
a certain chemical found in the tissue collected from small intestine and how they compare.
Intervention
Biopsy, Biospecimen Collection, Esophagogastroduodenoscopy, Linaclotide, Plecanatide
Condition
Barrett Esophagus, Gastroesophageal Reflux Disease
Investigators
David S Weinberg, Scott A. Waldman, David S. Weinberg